Format

Send to

Choose Destination
Cancer Sci. 2015 May;106(5):604-10. doi: 10.1111/cas.12642. Epub 2015 Apr 29.

Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.

Author information

1
Division of Gastrointestinal Oncology, National Cancer Center Hospital, Tokyo, Japan.
2
Division of Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.
3
Clinical Research Center, Chiba University Hospital, Chiba, Japan.
4
Division of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.
5
Division of Medical Oncology, Kochi Health Sciences Center, Kouch, Japan.

Abstract

Skin toxicity is a known clinical signature used to predict the prognosis of anti-epidermal growth factor receptor (EGFR) antibody treatment in metastatic colorectal cancer (mCRC). There are no biological markers to predict skin toxicity before anti-EGFR antibody treatment in mCRC patients. Between August 2008 and August 2011, pretreatment serum samples were obtained from KRAS wild-type (WT) patients who received anti-EGFR antibody treatment. Serum levels of ligands were measured by ELISA. A total of 103 KRAS WT patients were enrolled in the study. Progression-free survival and overall survival of patients with a high grade (grade 2-3) of skin toxicity were significantly longer than those with a low grade (grade 0-1) of skin toxicity (median progression-free survival, 6.4 months vs 2.4 months, P < 0.001; median overall survival, 14.6 months vs 7.1 months, P = 0.006). There were significant differences in distribution of serum levels of epiregulin (EREG), amphiregulin (AREG), and hepatocyte growth factor (HGF) between groups of low/high grade of skin toxicity (P < 0.048, P < 0.012, P < 0.012, respectively). In addition, serum levels of HGF, EREG, and AREG were inversely proportional to grades of skin toxicity as determined by the Cochran-Armitage test (P = 0.019, P = 0.047, P = 0.021, respectively). Our study indicated that serum levels such as HGF, EREG, and AREG may be significant markers to predict the grade of skin toxicity and the prognosis of anti-EGFR antibody treatment, which contribute to improvement of the management of skin toxicity and survival time in mCRC patients.

KEYWORDS:

Colorectal cancer; EGFR; KRAS; ligands; skin toxicity

PMID:
25707609
PMCID:
PMC4452162
DOI:
10.1111/cas.12642
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances

Publication types

MeSH terms

Substances

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center